Rik Ossenkoppele

Rik Ossenkoppele

Auto-generated profile, based on publicly available information

Rik Ossenkoppele

Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2016 in Brain
Verified
Journal Article
Open access
PDF file
RORik Ossenkoppele
Rik Ossenkoppele
DSDaniel R. Schonhaut
Daniel R. Schonhaut
MSMichael Schöll
Michael Schöll
SLSamuel N. Lockhart
Samuel N. Lockhart
NANagehan Ayakta
Nagehan Ayakta
GRGil D. Rabinovici
Gil D. Rabinovici
The advent of the positron emission tomography tracer 18F-AV1451 provides the unique opportunity to visualize the regional distribution of tau pathology in the living human brain. In this study, we tested the hypothesis that tau pathology is closely linked to symptomatology and patterns of glucose hypometabolism in Alzheimer’s disease, in contrast to the more diffuse distribution of amyloid-β pathology. We included 20 patients meeting criteria for probable Alzheimer’s disease dementia or mild cognitive impairment due to Alzheimer’s disease, presenting with a variety of clinical phenotypes, and 15 amyloid-β-negative cognitively normal individuals, who underwent 18F-AV1451 (tau), 11C-PiB (amyloid-β) and 18F-FDG (glucose metabolism) positron emission tomography, apolipoprotein E (APOE) genotyping and neuropsychological testing. Voxel-wise contrasts against controls (at P < 0.05 family-wise error corrected) showed that 18F-AV1451 and 18F-FDG patterns in patients with posterior cortical atrophy (‘visual variant of Alzheimer’s disease’, n = 7) specifically targeted the clinically affected posterior brain regions, while 11C-PiB bound diffusely throughout the neocortex. Patients with an amnestic-predominant presentation (n = 5) showed highest 18F-AV1451 retention in medial temporal and lateral temporoparietal regions. Patients with logopenic variant primary progressive aphasia (‘language variant of Alzheimer’s disease’, n = 5) demonstrated asymmetric left greater than right hemisphere 18F-AV1451 uptake in three of five patients. Across 30 FreeSurfer-defined regions of interest in 16 Alzheimer’s disease patients with all three positron emission tomography scans available, there was a strong negative association between 18F-AV1451 and 18F-FDG uptake (Pearson’s r = −0.49 ± 0.07, P < 0.001) and less pronounced positive associations between 11C-PiB and 18F-FDG (Pearson’s r = 0.16 ± 0.09, P < 0.001) and 18F-AV1451 and 11C-PiB (Pearson’s r = 0.18 ± 0.09, P < 0.001). Voxel-wise linear regressions thresholded at P < 0.05 (uncorrected) showed that, across all patients, younger age was associated with greater 18F-AV1451 uptake in wide regions of the neocortex, while older age was associated with increased 18F-AV1451 in the medial temporal lobe. APOE ϵ4 carriers showed greater temporal and parietal 18F-AV1451 uptake than non-carriers. Finally, worse performance on domain-specific neuropsychological tests was associated with greater 18F-AV1451 uptake in key regions implicated in memory (medial temporal lobes), visuospatial function (occipital, right temporoparietal cortex) and language (left > right temporoparietal cortex). In conclusion, tau imaging—contrary to amyloid-β imaging—shows a strong regional association with clinical and anatomical heterogeneity in Alzheimer’s disease. Although preliminary, these results are consistent with and expand upon findings from post-mortem, animal and cerebrospinal fluid studies, and suggest that the pathological aggregation of tau is closely linked to patterns of neurodegeneration and clinical manifestations of Alzheimer’s disease.

19 May 2015 in JAMA
Verified
Journal Article
Open access
PDF file
RORik Ossenkoppele
Rik Ossenkoppele
WJWillemijn J. Jansen
Willemijn J. Jansen
GRGil D. Rabinovici
Gil D. Rabinovici
DKDirk L. Knol
Dirk L. Knol
WFWiesje M. van der Flier
Wiesje M. van der Flier
DBDavid J. Brooks
David J. Brooks
More than 35 million people worldwide experience dementia, with Alzheimer disease (AD) hallmark pathologies amyloid-β plaques and neurofibrillary tangles as the most common cause.1 Accurately determining the cause of dementia during life is essential to developing and implementing disease-specific therapies. However, a diagnosis based on clinical criteria alone has limited capacity to determine the histopathological cause of dementia. For example, the clinical diagnosis of probable AD shows only modest sensitivity (71%-81%) and specificity (approximately 70%) against postmortem examination,2,3 which potentially confounds clinical trials in AD.4,5 Development of amyloid-β–specific positron emission tomography (PET) tracers6-9 now enable human in vivo detection of fibrillar amyloid-β in neuritic plaques. Incorporating amyloid imaging into the diagnostic workup can lead to change in diagnosis,10-12 increased diagnostic confidence,11 and altered patient management.10,12 Approval by the US Food and Drug Administration (FDA) for [18F]florbetapir (in 2012), [18F]flutemetamol (in 2013), and [18F]florbetaben (in 2014) supports potential application of amyloid imaging in clinical practice.13

25 May 2022 in The Lancet Neurology
Verified
Journal Article
Closed access
RORik Ossenkoppele
Rik Ossenkoppele
RKRik van der Kant
Rik van der Kant
OHOskar Hansson
Oskar Hansson

10 November 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RORik Ossenkoppele
Rik Ossenkoppele
ABAlexa Pichet Binette
Alexa Pichet Binette
CGColin Groot
Colin Groot
RSRuben Smith
Ruben Smith
OSOlof Strandberg
Olof Strandberg
OHOskar Hansson
Oskar Hansson
A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer’s disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A+) and tau PET-positive (T+) in the medial temporal lobe (A+TMTL+) and/or in the temporal neocortex (A+TNEO-T+) and compared them with A+T−and A−T−groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A+TNEO-T+(hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9–33.7), A+TMTL+(HR = 14.6, 95% CI = 8.1–26.4) and A+T−(HR = 2.4, 95% CI = 1.4–4.3) groups versus the A−T−(reference) group. Both A+TMTL+(HR = 6.0, 95% CI = 3.4–10.6) and A+TNEO-T+(HR = 7.9, 95% CI = 4.7–13.5) groups also showed faster clinical progression to mild cognitive impairment than the A+T−group. Linear mixed-effect models indicated that the A+TNEO-T+(β = −0.056 ± 0.005,T = −11.55,P < 0.001), A+TMTL+(β = −0.024 ± 0.005,T = −4.72,P < 0.001) and A+T−(β = −0.008 ± 0.002,T = −3.46,P < 0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A−T−(reference) group (allP < 0.001). Both A+TNEO-T+(P < 0.001) and A+TMTL+(P = 0.002) groups also progressed faster than the A+T−group. In summary, evidence of advanced Alzheimer’s disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3–5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.

2 July 2015 in Brain
Verified
Journal Article
Open access
PDF file
RORik Ossenkoppele
Rik Ossenkoppele
YPYolande A. L. Pijnenburg
Yolande A. L. Pijnenburg
DPDavid C. Perry
David C. Perry
BCBrendan I. Cohn-Sheehy
Brendan I. Cohn-Sheehy
NSNienke M. E. Scheltens
Nienke M. E. Scheltens
GRGil D. Rabinovici
Gil D. Rabinovici
A ‘frontal variant of Alzheimer’s disease’ has been described in patients with predominant behavioural or dysexecutive deficits caused by Alzheimer’s disease pathology. The description of this rare Alzheimer’s disease phenotype has been limited to case reports and small series, and many clinical, neuroimaging and neuropathological characteristics are not well understood. In this retrospective study, we included 55 patients with Alzheimer’s disease with a behavioural-predominant presentation (behavioural Alzheimer’s disease) and a neuropathological diagnosis of high-likelihood Alzheimer’s disease (n = 17) and/or biomarker evidence of Alzheimer’s disease pathology (n = 44). In addition, we included 29 patients with autopsy/biomarker-defined Alzheimer’s disease with a dysexecutive-predominant syndrome (dysexecutive Alzheimer’s disease). We performed structured chart reviews to ascertain clinical features. First symptoms were more often cognitive (behavioural Alzheimer’s disease: 53%; dysexecutive Alzheimer’s disease: 83%) than behavioural (behavioural Alzheimer’s disease: 25%; dysexecutive Alzheimer’s disease: 3%). Apathy was the most common behavioural feature, while hyperorality and perseverative/compulsive behaviours were less prevalent. Fifty-two per cent of patients with behavioural Alzheimer’s disease met diagnostic criteria for possible behavioural-variant frontotemporal dementia. Overlap between behavioural and dysexecutive Alzheimer’s disease was modest (9/75 patients). Sixty per cent of patients with behavioural Alzheimer’s disease and 40% of those with the dysexecutive syndrome carried at least one APOE ε4 allele. We also compared neuropsychological test performance and brain atrophy (applying voxel-based morphometry) with matched autopsy/biomarker-defined typical (amnestic-predominant) Alzheimer’s disease (typical Alzheimer’s disease, n = 58), autopsy-confirmed/Alzheimer’s disease biomarker-negative behavioural variant frontotemporal dementia (n = 59), and controls (n = 61). Patients with behavioural Alzheimer’s disease showed worse memory scores than behavioural variant frontotemporal dementia and did not differ from typical Alzheimer’s disease, while executive function composite scores were lower compared to behavioural variant frontotemporal dementia and typical Alzheimer’s disease. Voxel-wise contrasts between behavioural and dysexecutive Alzheimer’s disease patients and controls revealed marked atrophy in bilateral temporoparietal regions and only limited atrophy in the frontal cortex. In direct comparison with behavioural and those with dysexecutive Alzheimer’s disease, patients with behavioural variant frontotemporal dementia showed more frontal atrophy and less posterior involvement, whereas patients with typical Alzheimer’s disease were slightly more affected posteriorly and showed less frontal atrophy (P < 0.001 uncorrected). Among 24 autopsied behavioural Alzheimer’s disease/dysexecutive Alzheimer’s disease patients, only two had primary co-morbid FTD-spectrum pathology (progressive supranuclear palsy). In conclusion, behavioural Alzheimer’s disease presentations are characterized by a milder and more restricted behavioural profile than in behavioural variant frontotemporal dementia, co-occurrence of memory dysfunction and high APOE ε4 prevalence. Dysexecutive Alzheimer’s disease presented as a primarily cognitive phenotype with minimal behavioural abnormalities and intermediate APOE ε4 prevalence. Both behavioural Alzheimer’s disease and dysexecutive Alzheimer’s disease presentations are distinguished by temporoparietal-predominant atrophy. Based on the relative sparing of frontal grey matter, we propose to redefine these clinical syndromes as ‘the behavioural/dysexecutive variant of Alzheimer’s disease’ rather than frontal variant Alzheimer’s disease. Further work is needed to determine whether behavioural and dysexecutive-predominant presentations of Alzheimer’s disease represent distinct phenotypes or a single continuum.

21 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NBNicolas R. Barthélemy
Nicolas R. Barthélemy
GSGemma Salvadó
Gemma Salvadó
SSSuzanne E. Schindler
Suzanne E. Schindler
YHYingxin He
Yingxin He
SJShorena Janelidze
Shorena Janelidze
OHOskar Hansson
Oskar Hansson
With the emergence of Alzheimer’s disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. In this study, we evaluated whether a precise blood test could perform as well as established cerebrospinal fluid (CSF) tests in detecting amyloid-β (Aβ) plaques and tau tangles. Plasma %p-tau217 (ratio of phosporylated-tau217 to non-phosphorylated tau) was analyzed by mass spectrometry in the Swedish BioFINDER-2 cohort (n = 1,422) and the US Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) cohort (n = 337). Matched CSF samples were analyzed with clinically used and FDA-approved automated immunoassays for Aβ42/40 and p-tau181/Aβ42. The primary and secondary outcomes were detection of brain Aβ or tau pathology, respectively, using positron emission tomography (PET) imaging as the reference standard. Main analyses were focused on individuals with cognitive impairment (mild cognitive impairment and mild dementia), which is the target population for available disease-modifying treatments. Plasma %p-tau217 was clinically equivalent to FDA-approved CSF tests in classifying Aβ PET status, with an area under the curve (AUC) for both between 0.95 and 0.97. Plasma %p-tau217 was generally superior to CSF tests in classification of tau-PET with AUCs of 0.95–0.98. In cognitively impaired subcohorts (BioFINDER-2: n = 720; Knight ADRC: n = 50), plasma %p-tau217 had an accuracy, a positive predictive value and a negative predictive value of 89–90% for Aβ PET and 87–88% for tau PET status, which was clinically equivalent to CSF tests, further improving to 95% using a two-cutoffs approach. Blood plasma %p-tau217 demonstrated performance that was clinically equivalent or superior to clinically used FDA-approved CSF tests in the detection of AD pathology. Use of high-performance blood tests in clinical practice can improve access to accurate AD diagnosis and AD-specific treatments.